Patents Assigned to CHEMOMAB LTD.
  • Anti CCL24 (eotaxin2) antibodies for use in the treatment of hepatic diseases
    Patent number: 12018074
    Abstract: Provided concerns isolated anti CCL24 (eotaxin 2) antibodies for method of treatment of hepatic pathologies.
    Type: Grant
    Filed: June 20, 2022
    Date of Patent: June 25, 2024
    Assignee: CHEMOMAB LTD.
    Inventor: Adi Mor
  • METHOD OF TREATMENT USING ANTI-CCL24 ANTIBODY
    Publication number: 20230235037
    Abstract: Provided are compositions and methods for treating fibrotic inflammatory diseases, including non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc), with an anti-CCL24 monoclonal antibody.
    Type: Application
    Filed: April 20, 2021
    Publication date: July 27, 2023
    Applicant: CHEMOMAB LTD.
    Inventors: Adi MOR, Arnon AHARON, Sharon HASHMUELI, Michal SEGAL SALTO, Neta BARASHI
  • CCL24 INHIBITORS IN THE TREATMENT OF COVID-19
    Publication number: 20230192836
    Abstract: The invention concerns isolated monoclonal antibodies that bind to CCL24 (eotaxin 2) for use in the treatment of Covid-19.
    Type: Application
    Filed: April 20, 2021
    Publication date: June 22, 2023
    Applicant: CHEMOMAB LTD.
    Inventors: Adi MOR, Arnon AHARON, Michal SEGAL SALTO, Neta BARASHI
  • ANTI CCL24 (EOTAXIN2) ANTIBODIES FOR USE IN THE TREATMENT OF HEPATIC DISEASES
    Publication number: 20220372126
    Abstract: Provided concerns isolated anti CCL24 (eotaxin 2) antibodies for method of treatment of hepatic pathologies.
    Type: Application
    Filed: June 20, 2022
    Publication date: November 24, 2022
    Applicant: CHEMOMAB LTD.
    Inventor: Adi MOR
  • Anti CCL24 (EOTAXIN2) antibodies for use in the treatment of hepatic diseases
    Patent number: 11365246
    Abstract: Provided concerns isolated anti CCL24 (eotaxin 2) antibodies for method of treatment of hepatic pathologies.
    Type: Grant
    Filed: March 8, 2018
    Date of Patent: June 21, 2022
    Assignee: CHEMOMAB LTD.
    Inventor: Adi Mor
  • ANTI CCL24 (EOTAXIN2) ANTIBODIES FOR USE IN THE TREATMENT OF HEPATIC DISEASES
    Publication number: 20200040070
    Abstract: Provided concerns isolated anti CCL24 (eotaxin 2) antibodies for method of treatment of hepatic pathologies.
    Type: Application
    Filed: March 8, 2018
    Publication date: February 6, 2020
    Applicant: CHEMOMAB LTD.
    Inventor: Adi MOR
  • Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines
    Patent number: 10479830
    Abstract: The invention concerns isolated polyspecific antibodies directed to a unique epitope in the chemokine eotaxin 2, whereby the antibodies bind additional CCR3-binding chemokines. The invention further concerns use of these antibodies for attenuating the migration of various cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte related disorders or allergic atopic disorders.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: November 19, 2019
    Assignee: CHEMOMAB LTD.
    Inventor: Adi Mor
  • ANTI EOTAXIN-2 ANTIBODIES THAT RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES
    Publication number: 20190153088
    Abstract: The invention concerns isolated polyspecific antibodies directed to a unique epitope in the chemokine eotaxin 2, whereby the antibodies bind additional CCR3-binding chemokines. The invention further concerns use of these antibodies for attenuating the migration of various cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte related disorders or allergic atopic disorders.
    Type: Application
    Filed: February 7, 2019
    Publication date: May 23, 2019
    Applicant: CHEMOMAB LTD.
    Inventor: Adi MOR
  • Anti eotaxin-2 antibodies that recognize additional CCR3-binding chemokines
    Patent number: 10246508
    Abstract: Provided are isolated polyspecific antibodies directed to a unique epitope in the chemokine eotaxin 2. The antibodies bind additional CCR3-binding chemokines. Further provided are methods for using of the antibodies for attenuating the migration of various cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte related disorders or allergic atopic disorders.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: April 2, 2019
    Assignee: CHEMOMAB LTD.
    Inventor: Adi Mor
  • ANTI EOTAXIN-2 ANTIBODIES THAT RECOGNIZE ADDITIONAL CCR3-BINDING CHEMOKINES
    Publication number: 20160368979
    Abstract: Provided are isolated polyspecific antibodies directed to a unique epitope in the chemokine eotaxin 2. The antibodies bind additional CCR3-binding chemokines. Further provided are methods for using of the antibodies for attenuating the migration of various cells and for treating fibrotic diseases, autoimmune inflammatory disorders, monocyte related disorders or allergic atopic disorders.
    Type: Application
    Filed: March 4, 2015
    Publication date: December 22, 2016
    Applicant: CHEMOMAB LTD.
    Inventor: Adi MOR